EP1105406A4 - Novel esk potassium channel polypeptide and polynucleotide compositions - Google Patents

Novel esk potassium channel polypeptide and polynucleotide compositions

Info

Publication number
EP1105406A4
EP1105406A4 EP99941162A EP99941162A EP1105406A4 EP 1105406 A4 EP1105406 A4 EP 1105406A4 EP 99941162 A EP99941162 A EP 99941162A EP 99941162 A EP99941162 A EP 99941162A EP 1105406 A4 EP1105406 A4 EP 1105406A4
Authority
EP
European Patent Office
Prior art keywords
esk
novel
potassium channel
channel polypeptide
polynucleotide compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99941162A
Other languages
German (de)
French (fr)
Other versions
EP1105406A1 (en
Inventor
John R Forsayeth
Byron B Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharmaceuticals LLC
Original Assignee
Elan Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharmaceuticals LLC filed Critical Elan Pharmaceuticals LLC
Publication of EP1105406A1 publication Critical patent/EP1105406A1/en
Publication of EP1105406A4 publication Critical patent/EP1105406A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP99941162A 1998-08-14 1999-08-13 Novel esk potassium channel polypeptide and polynucleotide compositions Withdrawn EP1105406A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9657098P 1998-08-14 1998-08-14
US96570P 1998-08-14
PCT/US1999/018556 WO2000009534A1 (en) 1998-08-14 1999-08-13 Novel esk potassium channel polypeptide and polynucleotide compositions

Publications (2)

Publication Number Publication Date
EP1105406A1 EP1105406A1 (en) 2001-06-13
EP1105406A4 true EP1105406A4 (en) 2004-12-15

Family

ID=22257998

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99941162A Withdrawn EP1105406A4 (en) 1998-08-14 1999-08-13 Novel esk potassium channel polypeptide and polynucleotide compositions

Country Status (5)

Country Link
EP (1) EP1105406A4 (en)
JP (1) JP2003527818A (en)
AU (1) AU5487199A (en)
CA (1) CA2339406A1 (en)
WO (1) WO2000009534A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094948B2 (en) 2001-11-14 2006-08-22 Astellas Pharma, Inc. Transgenic animals
US8399663B2 (en) 2009-04-03 2013-03-19 Astellas Pharma Inc. Salt of 1,3,5-triazine-2,4,6-triamine derivative
WO2010137689A1 (en) * 2009-05-29 2010-12-02 アステラス製薬株式会社 Novel pharmaceutical composition for prevention and/or treatment of attention deficit/hyperactivity disorder

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999037677A1 (en) * 1998-01-23 1999-07-29 Yamanouchi Pharmaceutical Co., Ltd. Novel potassium channel protein

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5401629A (en) * 1990-08-07 1995-03-28 The Salk Institute Biotechnology/Industrial Associates, Inc. Assay methods and compositions useful for measuring the transduction of an intracellular signal
US5328830A (en) * 1992-09-08 1994-07-12 Miles Inc. Potassium channel modulators
US5599673A (en) * 1995-03-09 1997-02-04 University Of Utah Research Foundation Long QT syndrome genes
US5565483A (en) * 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999037677A1 (en) * 1998-01-23 1999-07-29 Yamanouchi Pharmaceutical Co., Ltd. Novel potassium channel protein

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO0009534A1 *

Also Published As

Publication number Publication date
WO2000009534A1 (en) 2000-02-24
EP1105406A1 (en) 2001-06-13
CA2339406A1 (en) 2000-02-24
AU5487199A (en) 2000-03-06
JP2003527818A (en) 2003-09-24

Similar Documents

Publication Publication Date Title
CY2506B1 (en) Composition
HU9602086D0 (en) Glass composition
ZA200101933B (en) Novel composition and use
PL329883A1 (en) Novel food composition
GB9809058D0 (en) Composition
HU9602087D0 (en) Glass composition
GB9812119D0 (en) Composition
GB9806788D0 (en) Composition
HUP9600148A2 (en) Glass composition
GB9827894D0 (en) Composition
EP1097166A4 (en) Potassium channel polypeptide and polynucleotide compositions
GB9806793D0 (en) Composition
EP1105406A4 (en) Novel esk potassium channel polypeptide and polynucleotide compositions
PL344137A1 (en) Novel composition
GB9914796D0 (en) Composition
EP1003527A4 (en) Polynucleotide compositions
GB9903310D0 (en) Composition
GB9804041D0 (en) Composition
GB9806791D0 (en) Composition
GB9800011D0 (en) Composition
GB9803982D0 (en) Composition
LT98061A (en) Material - fiber composition
GB9824867D0 (en) Novel composition and use
GB9824869D0 (en) Novel composition and use
GB9824870D0 (en) Novel composition and use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010212

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20041104

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050503